Press Releases

2015.03.26 Corporate PDF (64KB)
Announcement Regarding Closure of Merger Between Daiichi Sankyo Subsidiary Ranbaxy and Sun Pharma (Additional Disclosure)
2015.03.25 Corporate PDF (64KB)
Announcement Regarding Closure of Merger Between Daiichi Sankyo Subsidiary Ranbaxy and Sun Pharma
2015.03.20 Local (JPN) PDF (63KB)
Daiichi Sankyo Launches Methemoglobinemia Treatment Methylene Blue Injection 50mg
2015.03.20 Corporate PDF (48KB)
Daiichi Sankyo Signs Agreement with AstraZeneca to Co-commercialize MOVANTIK™ in the US
2015.03.17 Local (JPN) PDF (51KB)
Daiichi Sankyo to Facilitate New Drug Discovery in 2015 through Collaborative Research and Grants
2015.02.24 Corporate PDF (31KB)
Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2015
2015.02.24 Corporate PDF (76KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2015.02.09 Products PDF (163KB)
SAVAYSA™ (edoxaban) Now Available in U.S. Pharmacies
2015.02.04 R&D PDF (89KB)
Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
2015.01.29 IR PDF (455KB)
Ranbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec’14 Sales Rs.81,778 Mn
2015.01.13 Corporate PDF (42KB)
Daiichi Sankyo, Inc. Announces Civil Settlement
2015.01.09 Products PDF (139KB)
U.S. FDA Approves Daiichi Sankyo’s Once-Daily SAVAYSA™ (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism
2015.01.05 Local (JPN) PDF (18KB)
Daiichi Sankyo Receives Approval in Japan for the Manufacture and Marketing of Methemoglobinemia Treatment Methylene Blue Injection 50 mg

In order to view the PDF files, you need to have Adobe Reader 5.0 or later version installed.